Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

Dr Reddy’s delays semaglutide supplies due to API issue

MUMBAI: Dr Reddy’s Laboratories’ plans to capitalize on the early generic semaglutide market have hit a setback after manufacturing issues delayed supplies of the blockbuster diabetes and weight-loss drug, forcing…

India Tightens Rules On Alcohol-Containing Medicines

New rules on alcohol in medicine: The Centre has brought oral medicines containing more than 12% ethyl alcohol and sold in bottles larger than 30 ml under Schedule H1 In…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Dr Reddy’s delays semaglutide supplies due to API issue

Dr Reddy’s delays semaglutide supplies due to API issue

India Tightens Rules On Alcohol-Containing Medicines

India Tightens Rules On Alcohol-Containing Medicines

One more held in spurious plasma racket; police say he supplied 12 boxes

One more held in spurious plasma racket; police say he supplied 12 boxes

Wegovy, Ozempic regain weight as Indian generics fall behind

Wegovy, Ozempic regain weight as Indian generics fall behind

Drug regulator orders fresh safety labels for five common antimicrobials

Drug regulator orders fresh safety labels for five common antimicrobials

Rajasthan recalls labour-inducing drug after quality test failure

Rajasthan recalls labour-inducing drug after quality test failure